Komori
Treasury shares4547KISSEI PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding the Status of Share Repurchases

During October 2026, the company acquired 18,100 treasury shares through market purchases under a discretionary trading agreement. Cumulative acquisitions based on the board resolution reached 200,000 shares, with a cumulative acquisition cost of approximately ¥799 million.

Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
69273000
yen
Wording
Definitive
How definitive the wording is.

Progress against acquisition limit

Market purchases on the Tokyo Stock Exchange under a discretionary trading agreement for the acquisition of treasury shares

Resolved 11 May 2026 / Acquisition period 12 May 2026 to 31 December 2026

15.4%
Cumulative utilization rate
Limit1,100,000 株 remaining
Number of Shares1,300,000 shares (maximum)
13.3%
Cumulative utilization rate
Limit5,200,688,500 円 remaining
Amount¥6,000,000,000 (maximum)

The darker band is the portion acquired this time (1 October 2026 to 31 October 2026 (trade-date basis)). 株数と金額は、ほぼ同じ速さで消化されています。

Number of Shares
Limit1,300,000 shares (maximum)
Cumulative total200,000 shares (as of 31 October 2026)
Current18,100 shares
Amount
Limit¥6,000,000,000 (maximum)
Cumulative total¥799,311,500 (as of 31 October 2026)
Current¥69,273,000
Percentage of total issued shares3.14% (as a percentage of issued shares excluding treasury shares)
Average acquisition price for this transaction (calculated)¥3,827 per shareCurrent acquisition price ÷ current number of shares acquired

消化率と残りは、会社が示した累計・今回と上限から算出しています。進捗率=上限に対してどこまで使ったかの割合です。

Progress against acquisition limit
ItemDetails
Total number of shares acquired in this transaction18,100 shares
Total current acquisition price¥69,273,000
Acquisition date/acquisition period1 October 2026 to 31 October 2026 (trade-date basis)
Method of acquisitionMarket purchases on the Tokyo Stock Exchange under a discretionary trading agreement for the acquisition of treasury shares
Cumulative number of shares acquired200,000 shares (as of 31 October 2026)
Cumulative acquisition cost¥799,311,500 (as of 31 October 2026)
Resolution date11 May 2026
Maximum number of shares to be acquired1,300,000 shares (maximum)
Total acquisition price¥6,000,000,000 (maximum)
Acquisition period under the resolution12 May 2026 to 31 December 2026
Percentage of total issued shares3.14% (as a percentage of issued shares excluding treasury shares)
Items this document does not state (2)
Whether acquisition has been completedAverage Acquisition Price

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This reports the acquisition status and does not state a specific reason for the acquisitions.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Status of Share Repurchases | KISSEI PHARMACEUTICAL CO.,LTD. (4547) timely disclosure | Komori